ВОЗМОЖНОСТИ ТЕЛМИСАРТАНА В СНИЖЕНИИ СЕРДЕЧНО-СОСУДИСТОГО РИСКА

В статье рассмотрены вопросы клинической эффективности телмисартана — блокатора рецепторов ангиотензина II первого типа с точки зрения его влияния на сердечно-сосудистый риск у пациентов с артериальной гипертонией. Представлены результатымногочисленных исследований, свидетельствующие о мощных антигипертензивных и органопротективных свойствах телмисартана. Описаны возможности использования этого препарата у пациентов высокого риска, его эффективность в кардио- и нефропротекции. Особое внимание уделено исключительной способности телмисартана выступать в роли агониста PPAR γ-рецепторов и тем самым корригировать нарушения углеводного и липидного обменов у пациентов с метаболическим синдромом и сахарным диабетом.

1. Chazova IE, Ratova LG, Boitsov SA, Nebieridze DV. Recommendations for the management of arterial hypertension Russian Medical Society of Arterial Hypertension and Society of Cardiology of the Russian Federation. Sistemnye gipertenzii 2010; 3: 5-26. (in Russ.) Чазова И.Е., Ратова Л. Г., Бойцов С.А., Небиеридзе Д. В. Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии 2010; 3: 5-26.

2. Savoia C, Volpe M, Grassi G, et al. Personalized medicine-a modern approach for the diagnosis and management of hypertension. Clin Sci (Lond) 2017; 131 (22): 2671-85. DOI: 10.1042/CS20160407.

3. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies BMJ 2009; 338: b1665. DOI: 10.1136/bmj.b1665.

4. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-357. DOI: 10.1097/01.hjh.0000431740.32696.cc.

5. Galzerano D, Capogrosso C, Di Michele S, et al. New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag 2010; 6: 113-33. DOI: 10.2147/VHRM.S7857.

6. Ragot S, Ezzaher A, Meunier A, et al. Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study. J Hum Hypertens 2002; 16 (12): 865-73. DOI: 10.1038/sj.jhh.1001494

7. Neutel JM, Frishman WH, Oparil S, et al. Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Am J Ther 1999; 6: 161-6. DOI: 10.1097/00045391-199905000-00007.

8. Nishimura T, Hashimoto J, Ohkubo T, et al. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements. Clin Exp Hypertens 2005; 27 (6): 477-89. DOI: 10.1081/CEH-200067668.

9. Sasaki T, Noda Y, Yasuoka Y, et al. Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome. Hypertens Res 2008; 31 (5): 921-9. DOI: 10.1291/hypres.31.921.

10. Alcocer L, Fernández-Bonetti P, Campos E, et al. Clinical efficacy and safety of telmisartan 80 mg once daily vs. atenolol 50 mg once daily in patients with mild-tomoderate hypertension. Int J Clin Pract Suppl 2004; 145: 35-9. DOI: 10.1111/j.1742-1241.2004.00408.x.

11. Freytag F, Schelling A, Meinicke T, Deichsel G. Telmisartan Hypertension Experience in a Randomized European Study Versus Atenolol Study Group. Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study. Clin Ther 2001; 23 (1): 108-23. DOI: 10.1016/S0149-2918(01)80034-5.

12. Kakuta H, Sudoh K, Sasamata M, Yamagishi S. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005; 25 (1): 41-6.

13. Wienen W, Hauel N, Van Meel JC, et al. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol 1993; 110 (1): 245-52. DOI: 10.1111/j.1476-5381.1993.tb13800.x.

14. Parati G, Stergiou G, O’Brien E, et al. European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens 2014; 32 (7): 1359-66. DOI: 10.1097/HJH.0000000000000221.

15. Clement DL, De Buyzere ML, De Bacquer DA, et al. Office versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003; 348 (24): 2407-15. DOI: 10.1056/NEJMoa022273.

16. Sega R, Facchetti R, Bombelli M, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 2005; 111 (14): 1777-83. DOI: 10.1161/01.CIR.0000160923.04524.5B.

17. Niiranen TJ, Mäki J, Puukka P, et al. Office, home, and ambulatory blood pressures as predictors of cardiovascular risk. Hypertension 2014; 64 (2): 281-6. DOI: 10.1161/HYPERTENSIONAHA.114.03292.

18. White WB, Giles T, Bakris GL, et al. Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. Am Heart J 2006; 151 (1): 176-84. DOI: 10.1016/j.ahj.2005.02.014.

19. Williams B, Gosse P, Lowe L, Harper R; PRISMA I Study Group. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens 2006; 24 (1): 193-200. DOI: 10.1097/01.hjh.0000194364.11516.ab.

20. Lacourcière Y, Neutel JM, Davidai G, Koval S. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens 2006; 19 (1): 104-12. DOI: 10.1016/j.amjhyper.2005.10.001.

21. Lacourcière Y, Krzesinski JM, White WB, et al. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 2004; 9 (4): 203-10. DOI: 10.1097/00126097-200408000-00005.

22. Smith DH, Cramer MJ, Neutel JM, et al. Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. Blood Press Monit 2003; 8 (3): 111-7. DOI: 10.1097/00126097-200306000-00004.

23. Ding PY, Chu KM, Chiang HT, Shu KH. A double-blind ambulatory blood pressure monitoring study of the efficacy and tolerability of once-daily telmisartan 40 mg in comparison with losartan 50 mg in the treatment of mild-to-moderate hypertension in Taiwanese patients. Int J Clin Pract Suppl 2004; 145: 16-22. DOI: 10.1111/j.1742-1241.2004.00405.x.

24. Derosa G, Ragonesi PD, Mugellini A, et al. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004;27(7):457-64. DOI: 10.1291/hypres.27.457

25. Brunner HR. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. J Hum Hypertens 2002;16 Suppl 2:S13-6. DOI: 10.1038/sj.jhh.1001391

26. Peixoto AJ, White WB. Circadian blood pressure: clinical implications based on the pathophysiology of its variability. Kidney Int 2007; 71 (9): 855-60. DOI: 10.1038/sj.ki.5002130.

27. Willich SN, Levy D, Rocco MB, et al. Circadian variation in the incidence of sudden cardiac death in the Framingham Heart Study population. Am J Cardiol 1987; 60: 801-6. DOI: 10.1016/0002-9149(87)91027-7.

28. Willich SN, Lewis M, Lowel H, et al. Physical exertion as a trigger of acute myocardial infarction. N Engl J Med 1993; 329: 1684-90. DOI: 10.1056/NEJM199312023292302

29. Elliott WJ. Circadian variation in the timing of stroke onset. А meta-analysis. Stroke 1998; 29: 992-6. DOI: 10.1161/01.STR.29.5.992.

30. Kario K. Morning surge in blood pressure and cardiovascular risk: evidence and perspectives. Hypertension 2010; 56 (5): 765-73. DOI: 10.1161/HYPERTENSIONAHA.110.157149.

31. Lacourcière Y, Lenis J, Orchard R, et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press Monit 1998; 3 (5): 295-302.

32. Neldam S, Edwards C. ATHOS Study Group. Telmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring study. Am J Geriatr Cardiol 2006; 15 (3): 151-60. DOI: 10.1111/j.1076-7460.2006.05219.x.

33. Petrovic I, Petrovic D, Vukovic N, et al. Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients. J Int Med Res 2005; 33 (Suppl 1): 39A-49A. DOI: 10.1177/14732300050330S106.

34. Galzerano D, Tammaro P, del Viscovo L, et al. Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study. Am J Hypertens 2005; 18 (12 Pt 1): 1563-9. DOI: 10.1016/j.amjhyper.2005.06.011.

35. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372 (9644): 1174-83. DOI: 10.1016/S0140-6736(08)61242-8.

36. Redon J, Luque-Otero M, Martell N, Chaves FJ. POLPRI Investigators. Reninangiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. Pharmacogenomics J 2005; 5 (1): 14-20. DOI: 10.1038/sj.tpj.6500280.

37. Bakris G, Burgess E, Weir M, et al. AMADEO Study Investigators. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 2008; 74 (3): 364-9. DOI: 10.1038/ki.2008.204.

38. Schmieder RE, Delles C, Mimran A, et al. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 2007; 30 (6): 1351-6. DOI: 10.2337/dc06-1551.

39. Cupisti A, Rizza GM, D’Alessandro C, et al. Effect of telmisartan on the proteinuria and circadian blood pressure profile in chronic renal patients. Biomed Pharmacother 2003; 57 (3-4): 169-72. DOI: 10.1016/S0753-3322(03)00013-1.

40. Rysavá R, Tesar V, Merta M; Czech Group for the Study of Glomerulonephritis. Effect of telmisartan on blood pressure control and kidney function in hypertensive, proteinuric patients with chronic kidney disease. Blood Press Monit 2005; 10 (4): 207-13.

41. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37 (5): 1236-41. DOI: 10.1161/01.HYP.37.5.1236.

42. Kinouchi K, Ichihara A, Sakoda M, et al. Effects of telmisartan on arterial stiffness assessed by the cardio-ankle vascular index in hypertensive patients. Kidney Blood Press Res 2010; 33 (4): 304-12. DOI: 10.1159/000316724.

43. Asmar R, Gosse P, Topouchian J, et al. Effects of telmisartan on arterial stiffness in Type 2 diabetes patients with essential hypertension. J Renin Angiotensin Aldosterone Syst 2002; 3 (3): 176-80. DOI: 10.3317/jraas.2002.038.

44. Jugdutt BI. Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly. Clin Interv Aging 2010; 5: 403-16. DOI: 10.2147/CIA.S6709.

45. Vitale C, Mercuro G, Castiglioni C, et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovascular Diabetology 2005; 4: 6. DOI: 10.1186/1475-2840-4-6.

46. Miura Y, Yamamoto N, Tsunekawa S, et al. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care 2005; 28 (3): 757-8. DOI: 10.2337/diacare.28.3.757.

47. Derosa G, Cicero AF, D’Angelo A, et al. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. Hypertens Res 2006; 29 (11): 849-56. DOI: 10.1291/hypres.29.849.

48. Derosa G, Cicero AF, Bertone G, et al. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. Clin Ther 2004; 26 (8): 1228-36. DOI: 10.1016/S0149-2918(04)80049-3.

49. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358 (15): 1547-59. DOI: 10.1056/NEJMoa0801317.

50. Michel MC, Bohner H, Köster J, et al. Safety of telmisartan in patients with arterial hypertension : an open-label observational study. Drug Saf 2004; 27: 335-44. DOI: 10.2165/00002018-200427050-00005.